Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cumberland Pharma Acquires Astellas’ Vaprisol | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cumberland Pharma Acquires Astellas’ Vaprisol

Assumes responsibility for marketing, distribution and manufacture

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cumberland Pharmaceuticals, Inc. has acquired Vaprisol from Astellas Pharma US, Inc. Vaprisol is one of two branded prescription products indicated for the treatment of hyponatremia, an electrolyte disturbance associated with congestive heart failure, liver failure, kidney failure and pneumonia. The product was developed and registered by Astellas and was launched in 2006. 
 
Cumberland will assume full responsibility for marketing, distribution and manufacture. Cumberland will promote Vaprisol in the U.S. through its hospital sales force, which also features its Caldolor and Acetadote brands.
 
“We believe Vaprisol is an excellent strategic fit with our focus on hospital acute care,” said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. “Our immediate plan for Vaprisol is to ensure a smooth transition of the product supply and medical support to current users of the brand. We will then launch our hospital promotion support and are very optimistic about the opportunity that Vaprisol will offer Cumberland.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics